Drug class in one race
EGFR/HER2 drugs for Non-Small Cell Lung Cancer
4 tracked EGFR/HER2 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the EGFR/HER2 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 Phase 31 Phase 21 Phase 1/21 Phase 1
Head-to-head evidence: Neratinib vs ORIC-114 · Neratinib vs STX-721 · Neratinib vs Sevabertinib